Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey

Basit Öğe Kaydı
dc.contributor.authorKarakoyun, Miray
dc.contributor.authorOnen, Sebnem
dc.contributor.authorBaran, Masallah
dc.contributor.authorCakir, Murat
dc.contributor.authorEcevit, Cigdem Omur
dc.contributor.authorKilic, Murat
dc.contributor.authorKantar, Mehmet
dc.contributor.authorAksoylar, Serap
dc.contributor.authorOzgenc, Funda
dc.contributor.authorAydogdu, Sema
dc.date.accessioned2019-10-27T10:46:29Z
dc.date.available2019-10-27T10:46:29Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/Aims: A liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in long-term survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. Materials and Methods: The study group consisted of 206 liver transplant recipients, with no history of cancer, including hepatocellular carcinoma, in two liver transplantation centers in Turkey between 1997 and 2015. Data were obtained from patient's data chart. Results: In the study group, de novo cancer was diagnosed in 13 of the 206 patients. Post-transplant lymphoproliferative disease (PTLD) occurred in seven (53.8%) patients and other malignancies in six of the 13 patients. The types of PTLD were as follows: B-cell origin (n= 2), Epstein-Barr virus (EBV)-related (n= 2), T-cell origin (n= 1), and Hodgkin's lymphoma (n= 2). EBV DNA was isolated from seven patients, three of whom developed PTLD. The others developed Kaposi's sarcomas, Burkitt's lymphomas, cutaneous large-cell lymphomas, Hodgkin's lymphomas, and liver sarcomas. Conclusion: After transplantation, immunosuppressive treatment is unavoidable, increasing the risk of malignancies. However, a close follow-up and periodic screening can reduce cancer-related mortality and morbidity.en_US
dc.identifier.doi10.5152/tjg.2017.17089
dc.identifier.endpage93en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue1en_US
dc.identifier.pmid29391313en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage89en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2017.17089
dc.identifier.urihttps://hdl.handle.net/11454/31304
dc.identifier.volume29en_US
dc.identifier.wosWOS:000427075700013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectImmunosuppressionen_US
dc.subjectmalignancyen_US
dc.subjectliver transplantationen_US
dc.titlePost-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu